Martínez-López F, Oñate-Sánchez
R, Arrieta-Blanco JJ, Oñate-Cabrerizo D, Cabrerizo-Merino MC. Clinical diseases with thrombotic risk and their pharmacologycal
treatment: How they change the therapeutic attitude in dental treatments. Med Oral Patol
Oral Cir Bucal. 2013 Nov 1;18 (6):e888-95.
doi:10.4317/medoral.19561
http://dx.doi.org/doi:10.4317/medoral.19561
|
1. Pototski M, Amenábar
JM. Dental management of patients receiving anticoagulation or anti-platelet
treatment. J Oral Sci.
2007;49:253-8. |
||||
|
|
||||
|
2. Michelson AD. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008;28:s33-8. |
||||
|
|
||||
|
3. Fintel DJ. Oral antiplatelet
therapy for atherothrombotic disease: overview of
current and emerging treatment options. Vasc Health
Risk Manag. 2012;8:77-89. |
||||
|
|
||||
|
4. John J, Koshy SK. Current oral antiplatelets: focus update on prasugrel.
J Am Board Fam Med. 2012;25:343-9. |
||||
|
|
||||
|
5. Lazar LD, Lincoff AM.
Prasugrel for acute coronary syndromes: faster,
more potent, but higher bleeding risk. Cleve Clin J Med. 2009;76:707-14. |
||||
|
|
||||
|
6. Hall R, Mazer CD. Antiplatelet
drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112:292-318. |
||||
|
|
||||
|
7. Schafer JA, Kjesbo NK, Gleason PP.
Critical review of prasugrel for formulary decision
makers. J Manag
Care Pharm. 2009;15:335-43. |
||||
|
|
||||
|
8. Jakubowski JA, Riesmeyer
JS, Close SL, Leishman AG, Erlinge
D. Triton and beyond: new insights into the profile of prasugrel.
Cardiovasc Ther. 2012;30:174-82. |
||||
|
|
||||
|
9. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK,
Cornel JH, et al. Bleeding complica-tions with the
P2Y12 receptor antagonist clopidogrel and ticagrelor in Platelet inhibition and patient outcomes
(PLATO) trial. Eur Heart J. 2011;32:2933-44. |
||||
|
|
||||
|
10. Quinlan DJ, Eikelboom JW, Goodman SG,
Welsh RC, Fitchett DH, Théroux
P, et al. Implica-tions of variability in
definition and reporting of major bleeding in randomized trials of oral P2Y12
inhibitors for acute coronary syndromes. Eur Heart
J. 2011;32:2256-65. |
||||
|
|
||||
|
11. Hong CH, Nape-as JJ, Brennan MT, Furney
SL, Lockhart PB. Frequency of bleeding following invasive dental procedures
in patients on low-molecular-weight heparin ther-apy.
J Oral Maxillofac
Surg. 2010;68:975-9. |
||||
|
|
||||
|
12. Jiménez Y, Poveda
R, Gavaldá C, Margaix M, Sarrión G. An update on the management of anticoagulated patients programmed for dental extractions
and surgery. Med Oral Patol Oral Cir
Bucal. 2008;13:E176-9. |
||||
|
|
||||
|
13. Vicente Barrero M, Knezevic M, Tapia Martín M, Viejo Llorente A, Orengo Valverde JC, García Jiménez F, et al. Oral surgery in
patients undergoing oral anticoagulant therapy. Med Oral. 2002;7:63-70. |
||||
|
|
||||
|
14. Prasad V, Kaplan RM, Passman RS. New
frontiers for stroke prevention in atrial
fibrillation. Cerebrovasc Dis. 2012;33:199-208. |
||||
|
|
||||
|
15. Zapata-Wainberg G, Ximénez-Carrillo
Rico A, Vivancos-Mora J. [Clinical
management of the new anticoagulants]. Neurologia.
2012;27 Suppl 1:33-8. |
||||
|
|
||||
|
16. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural
bleeding and thromboembolic events with Dabigatran compared with warfarin:
results from the randomized evaluation of long-term anticoagulation therapy
(RE-LY) randomized trial. Circulation.
2012;126:343-8 |
||||
|
|
||||
|
17. Harenberg J, Marx S, Krejczy
M, Wehling M. New anticoagulants promising and
failed devel-opments. Br J Pharmacol.
2012;165:363-72. |
||||
|
|
||||
|
18. Wanek MR, Horn ET, Elapavaluru
S, Baroody SC, Sokos G.
Safe use of hemodialysis for dabigatran
removal before cardiac surgery. Ann Pharmacother.
2012;46:e21. |
||||
|
|
||||
|
19. Schulman S, Crowther MA. How I treat
anticoagulants in 2012: new and old anticoagulants, and when and how to
switch. Blood. 2012;119:3016-23. |
||||
|
|
||||
|
20. Norgard NB, Dinicolantonio
JJ, Topping TJ, Wee B. Novel anticoagulants in atrial
fibrillation stroke prevention. Ther Adv Chronic
Dis. 2012;3:123-36. |
||||
|
|
||||
|
21. Koskinas KC, Lillis T, Tsirlis A, Katsiki N, Giannoglou GD, Ziakas AG. Dental
manage-ment of antiplatelet-receiving
patients: is uninterrupted antiplatelet therapy
safe? Angiology. 2012;63:245-7. |
||||
|
|
||||
|
22. Douketis JD, Spyropoulos
AC, Spencer FA, Mayr M, Jaffer
AK, Eckman MH, et al. Perioperative
management of antithrombotic therapy: Antithrombotic Therapy and Prevention
of Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-50S. |
||||
|
|
||||
|
23. Pereira CM, Gasparetto PF, Carneiro DS, Corrêa
ME, Souza CA. Tooth extraction in patients on oral anticoagulants: prospective study
conducted in 108 brazilian patients. ISRN Dent. 2011;2011:203619. |
||||
|
|
||||
|
24. Spyropoulos AC, Douketis
JD. How I treat anticoagulated patients undergoing
an elective pro-cedure or surgery. Blood. 2012;120:2954-62. |
||||
|
|
||||
|
25. Rodríguez-Cabrera
MA, Barona-Dorado C, Leco-Berrocal I, Gómez-Moreno G, Martínez-González JM. Extraction
without eliminating anticoagulant treatment: a literatura
review. Med Oral Patol Oral Cir Bucal.
2011;16:e800-4. |
||||
|
|
||||
|
26. Tuvignon N, Liguory
C, Ponchon T, Meduri B,
Fritsch J, Sahel J, et al. Endoscopy and anti-platelet agents. European
Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2011;43:445-61. |
||||
|
|
||||
|
27. Lillis T, Ziakas A, Koskinas
K, Tsirlis A, Giannoglou
G. Safety of dental extractions during uninterrupted single or dual antiplatelet treatment. Am J Cardiol.
2011;108:964-7. |
||||
|
|
||||
|
28. Cardona-Tortajada F, Sainz-Gómez E, Figuerido-Garmendia
J, de Robles-Adsuar AL, Morte-Casabó
A, Giner-Mu-oz F, et al. Dental extractions in patients on antiplatelet therapy. A study con-ducted by the Oral
Health Department of the Navarre Health Service (Spain). Med Oral Patol Oral Cir
Bucal. 2009;14:e588-92. |
||||
|
|
||||
|
29. Park MW, Her SH, Kwon JB, Lee JB, Choi
MS, Cho JS, et al. Safety of dental extractions in coronary drug-eluting stenting patients without stopping multiple antiplatelet agents. Clin Cardiol. 2012;35:225-30. |
||||
|
|
||||
|
30. Ca-igral A, Silvestre FJ, Ca-igral G, Alós M, Garcia-Herraiz A, Plaza A. Evaluation of bleeding risk and
measurement methods in dental patients. Med
Oral Patol Oral Cir Bucal. 2010;15:e863-8. |
||||
|
|
||||
|
31. García DA, Granger CB. Anticoagulation,
novel agents and procedures: can we pardon the interruption?.
Circulation. 2012;126:255-7. |
||||
|
|
||||
|
32. Firriolo FJ, Hupp
WS. Beyond warfarin: the new generation of oral
anticoagulants and their implications for the management of dental patients.
Oral Surg Oral Med Oral Pathol
Oral Radiol. 2012;113:431-41. |
||||
|
|
||||
|
33. Scully C, Wolff A. Oral surgery in patients on anticoagulant
therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:57-64. |
||||
|
|
||||